Compare Adobe Systems Inc (ADBE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Sana Biotechnology Inc — how do they compare? Adobe Systems Inc trades at $258.34 (market cap $104.82B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Adobe Systems Inc is far larger — about 92.8× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| ADBE | SANA | |
|---|---|---|
Market Cap | $104.82B | $1.13B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $5.92 |
52-Week Low | $193.41 | $2.68 |
Enterprise Value | $106.26B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) trades at $263.71, down 3.39% on the day, with the stock showing mixed technical signals amid a bullish overall trend. Fundamentally, the company demonstrates strong profitability with a 28.69% net income margin and consistent earnings beats, though recent news highlights AI competition concerns. Revenue growth remains robust at $23.77 billion for 2025, while valuation metrics like a P/E of 15.09 appear reasonable relative to historical levels.
The outlook for ADBE is cautiously optimistic with solid fundamentals offset by near-term AI disruption fears. Investment opportunity lies in the company's strong cash flow generation and market leadership, while risks include competitive pressure from AI tools and CEO transition uncertainty. Analyst consensus remains favorable with 49.2% buy ratings, though the stock trades below the $248.86 consensus price target.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
